Fabrizio Citarella

15PUBLICATIONS
130CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 14, 2026
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.

|May 04, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Feb 26, 2026
Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer.

Matteo Canale, Fabrizia Suzzi, Alberto Verlicchi

|Aug 19, 2025
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.

Amin H Nassar, Chul Kim, Tolulope Adeyelu

|Jul 12, 2025
TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis.

Leonardo Brunetti, Valentina Santo, Alessandro Galletti

Pageof 3

Frequent Collaborators

6 joint publications

Alessio Cortellini

2 joint publications

Alessandro Galletti

2 joint publications

David J Pinato

2 joint publications

Raffaele Giusti